CCR2 and neoplasm: Firstly, we pretreated the BM cells with a CCR2 antagonist RS 102895 and evaluated BM cell migration to the tumor/stroma cocultures (HSC-2 + HDF, HSC-2 + PDS1, and HSC-2 + PDS2) (Figure 5G).